331 related articles for article (PubMed ID: 36717836)
1. Multi-omics analyses of CD276 in pan-cancer reveals its clinical prognostic value in glioblastoma and other major cancer types.
Dai L; Guo X; Xing Z; Tao Y; Liang W; Shi Z; Hu W; Zhou S; Wang X
BMC Cancer; 2023 Jan; 23(1):102. PubMed ID: 36717836
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis Reveals Distinct Immunological and Prognostic Characteristics of CD276/B7-H3 in Pan-Cancer.
Ding J; Sun Y; Sulaiman Z; Li C; Cheng Z; Liu S
Int J Gen Med; 2023; 16():367-391. PubMed ID: 36756390
[TBL] [Abstract][Full Text] [Related]
3. Histone acetylation gene-based biomarkers as novel markers of the immune microenvironment in glioblastoma.
Yan X; Feng L; Xu Z; Chen W; Yan H; Wu P; Ding C; Zhu X; Lu Y
J Gene Med; 2023 Oct; 25(10):e3511. PubMed ID: 37097165
[TBL] [Abstract][Full Text] [Related]
4. Tetraspanins predict the prognosis and characterize the tumor immune microenvironment of glioblastoma.
Li YC; Wu Y; Chen G; Zhu LZ; Luo X; Nie QQ; Zhang L; Zuo CJ
Sci Rep; 2023 Aug; 13(1):13317. PubMed ID: 37587203
[TBL] [Abstract][Full Text] [Related]
5. A pan-cancer analysis to determine the prognostic analysis and immune infiltration of HSPA5.
Zhu RK; Zhang W; Zhang YX; Hui Z; Wang XW
Curr Cancer Drug Targets; 2023 May; ():. PubMed ID: 37157205
[TBL] [Abstract][Full Text] [Related]
6. Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies.
Miller CD; Lozada JR; Zorko NA; Elliott A; Makovec A; Radovich M; Heath EI; Agarwal N; Mckay RR; Garje R; Bastos BR; Hoon DSB; Orme JJ; Sartor O; VanderWalde A; Nabhan C; Sledge G; Shenderov E; Dehm SM; Lou E; Miller JS; Hwang JH; Antonarakis ES
Cancer Res Commun; 2024 May; 4(5):1369-1379. PubMed ID: 38709075
[TBL] [Abstract][Full Text] [Related]
7. Expression of hub genes of endothelial cells in glioblastoma-A prognostic model for GBM patients integrating single-cell RNA sequencing and bulk RNA sequencing.
Zhao S; Ji W; Shen Y; Fan Y; Huang H; Huang J; Lai G; Yuan K; Cheng C
BMC Cancer; 2022 Dec; 22(1):1274. PubMed ID: 36474171
[TBL] [Abstract][Full Text] [Related]
8. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of carboxypeptidase Q and its methylation in glioblastoma.
Liu Q; Wang R; Li Z; Peng Y; Qin W; Peng XM; Liu ZG
Transl Cancer Res; 2023 May; 12(5):1073-1087. PubMed ID: 37304538
[TBL] [Abstract][Full Text] [Related]
10. Multi-omics analysis predicts fibronectin 1 as a prognostic biomarker in glioblastoma multiforme.
Kabir F; Apu MNH
Genomics; 2022 May; 114(3):110378. PubMed ID: 35513291
[TBL] [Abstract][Full Text] [Related]
11. CD276 and the gene signature composed of GATA3 and LGALS3 enable prognosis prediction of glioblastoma multiforme.
Takashima Y; Kawaguchi A; Hayano A; Yamanaka R
PLoS One; 2019; 14(5):e0216825. PubMed ID: 31075138
[TBL] [Abstract][Full Text] [Related]
12. Bioinformatics analyses of significant genes, related pathways and candidate prognostic biomarkers in glioblastoma.
Zhou L; Tang H; Wang F; Chen L; Ou S; Wu T; Xu J; Guo K
Mol Med Rep; 2018 Nov; 18(5):4185-4196. PubMed ID: 30132538
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of the prognosis and immune infiltrates for the BET protein family reveals the significance of BRD4 in glioblastoma multiforme.
Ye Y; Zhong W; Qian J; Zhang J; Xu T; Han R; Han J; Wang C; Song L; Zeng X; Wang H
Front Cell Dev Biol; 2023; 11():1042490. PubMed ID: 36711038
[No Abstract] [Full Text] [Related]
14. Exploring the potential biomarkers for prognosis of glioblastoma via weighted gene co-expression network analysis.
Zhang M; Zhou Z; Liu Z; Liu F; Zhao C
PeerJ; 2022; 10():e12768. PubMed ID: 35111402
[TBL] [Abstract][Full Text] [Related]
15. Construction of an immune-related gene signature for the prognosis and diagnosis of glioblastoma multiforme.
Yu Z; Yang H; Song K; Fu P; Shen J; Xu M; Xu H
Front Oncol; 2022; 12():938679. PubMed ID: 35982954
[TBL] [Abstract][Full Text] [Related]
16. Identification of potential crucial genes and molecular mechanisms in glioblastoma multiforme by bioinformatics analysis.
Chen X; Pan Y; Yan M; Bao G; Sun X
Mol Med Rep; 2020 Aug; 22(2):859-869. PubMed ID: 32467990
[TBL] [Abstract][Full Text] [Related]
17. Identifying key genes of classic papillary thyroid cancer in women aged more than 55 years old using bioinformatics analysis.
Li CC; Ullah MHE; Lin X; Shan SK; Guo B; Zheng MH; Wang Y; Li F; Yuan LQ
Front Endocrinol (Lausanne); 2022; 13():948285. PubMed ID: 36120433
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel prognostic targets in glioblastoma using bioinformatics analysis.
Yin X; Wu Q; Hao Z; Chen L
Biomed Eng Online; 2022 Apr; 21(1):26. PubMed ID: 35436915
[TBL] [Abstract][Full Text] [Related]
19. Elevated Expression of the Immune Checkpoint Ligand CD276 (B7-H3) in Urothelial Carcinoma Cell Lines Correlates Negatively with the Cell Proliferation.
Harland N; Maurer FB; Abruzzese T; Bock C; Montes-Mojarro IA; Fend F; Aicher WK; Stenzl A; Amend B
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563359
[TBL] [Abstract][Full Text] [Related]
20. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
